Markers of endothelial cell activation are associated with the severity of pulmonary disease in COVID-19
Open Access
- 19 May 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0268296
Abstract
Severe coronavirus disease-19 (COVID-19) is characterized by vascular inflammation and thrombosis. We and others have proposed that the inflammatory response to coronavirus infection activates endothelial cells, leading to endothelial release of pro-thrombotic proteins. These mediators can trigger obstruction of the pulmonary microvasculature, leading to worsening oxygenation, acute respiratory distress syndrome, and death. In the current study, we tested the hypothesis that higher levels of biomarkers released from endothelial cells are associated with worse oxygenation in patients with COVID-19. We studied 83 participants aged 18–84 years with COVID-19 admitted to a single center. The severity of pulmonary disease was classified by oxygen requirement, including no oxygen requirement, low-flow oxygen, high-flow nasal cannula oxygen, mechanical ventilation, and death. We measured plasma levels of two proteins released by activated endothelial cells, von Willebrand Factor (VWF) antigen and soluble P-Selectin (sP-Sel), and a biomarker of systemic thrombosis, D-dimer. Additionally, we explored the association of endothelial biomarker levels with the levels of pro-inflammatory cytokine and chemokines, and vascular inflammation biomarkers. We found that levels of VWF, sP-sel, and D-dimer were increased in individuals with more severe COVID-19 pulmonary disease. Biomarkers of endothelial cell activation were also correlated with proinflammatory cytokines and chemokines. Taken together, our data demonstrate increased levels of VWF and sP-selectin are linked to the severity of lung disease in COVID-19 and correlated with biomarkers of inflammation and vascular inflammation. Our data support the concept that COVID-19 is a vascular disease which involves endothelial injury in the context of an inflammatory state.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01 HL134894)
- National Heart, Lung, and Blood Institute (R61 HL141791)
This publication has 29 references indexed in Scilit:
- Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysisThrombosis Research, 2020
- Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysisJMV-Journal de Médecine Vasculaire, 2020
- Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19New England Journal of Medicine, 2020
- More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond ChemotaxisFrontiers in Immunology, 2019
- Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasisJournal of Thrombosis and Haemostasis, 2012
- von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older populationJournal of Thrombosis and Haemostasis, 2012
- Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flowBlood, 2004
- Correlation between cholesterol, soluble P-selectin, and D-dimer in obese children and adolescentsBlood Coagulation & Fibrinolysis, 2000
- TNF-α Stimulation of MCP-1 Expression Is Mediated by the Akt/PKB Signal Transduction Pathway in Vascular Endothelial CellsBiochemical and Biophysical Research Communications, 2000
- Von Willebrand Factor and the EndotheliumMayo Clinic Proceedings, 1991